Story perspectives

Life Biosciences Treats First Patient in Glaucoma Gene Therapy Trial

6/11/2026

Summary

Story summary

U.S. biotech Life Biosciences treated the first patient in a glaucoma gene-therapy trial with ER-100.
ER-100 activates three genes to partially reprogram retinal ganglion cells.
ER-100 is delivered by a non-infectious virus that works only while patients take an antibiotic.
The FDA approved the trial on January 15 and will enroll up to 18 participants.
Chief scientific officer Sharon Rosenzweig-Lipson notes regeneration, warns of cancer and no reduction, making safety.

1 of 1

Story summary

U.S. biotech Life Biosciences treated the first patient in a glaucoma gene-therapy trial with ER-100.
ER-100 activates three genes to partially reprogram retinal ganglion cells.
ER-100 is delivered by a non-infectious virus that works only while patients take an antibiotic.
The FDA approved the trial on January 15 and will enroll up to 18 participants.
Chief scientific officer Sharon Rosenzweig-Lipson notes regeneration, warns of cancer and no reduction, making safety.